Formycon Reports Positive Phase III Data On Ustekinumab
Company Is Looking For Marketing Partner On Stelara Biosimilar By Year End
Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.
You may also be interested in...
Formycon Concludes Successful Development Of Stelara Biosimilar Ahead Of Annual Results
Formycon has successfully concluded the development of its ustekinumab biosimilar FYB202, with regulatory submissions planned for Q3. It is just one of many biosimilar candidates which the German firm expects to soon start making significant revenue contributions.
Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.
Hikma Taps Celltrion Again To Bring In MENA Stelara Biosimilar
Hikma has signed another partnership agreement to gain Middle East and North Africa commercialization rights to an ustekinumab biosimilar – although not with its US partner, Bio-Thera Solutions.